[
  {
    "ts": null,
    "headline": "RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?",
    "summary": "Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.",
    "url": "https://finnhub.io/api/news?id=f12b7714d439ea56b0fc3578799d56f7a9ab224292d5cb68f7d97af2372a6326",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756146180,
      "headline": "RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?",
      "id": 136522377,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.",
      "url": "https://finnhub.io/api/news?id=f12b7714d439ea56b0fc3578799d56f7a9ab224292d5cb68f7d97af2372a6326"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=b3de4c59a26b7f2b3d8aa0bf0f15069f5b5d64ec33c42a05b6215ff4a1e40d93",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756139940,
      "headline": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
      "id": 136545125,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=b3de4c59a26b7f2b3d8aa0bf0f15069f5b5d64ec33c42a05b6215ff4a1e40d93"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global Targeted Drug Delivery Market Size/Share Worth USD 39.6 Billion by 2034 at a 15.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Targeted Drug Delivery Market size & share revenue was valued at approximately USD 9.8 Billion in 2024 and is expected to reach USD 11.4 Billion in 2025 and is expected to reach around USD 39.6 Billion by 2034, at a CAGR of 15.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Bristol-Myers Squibb, Pfiz",
    "url": "https://finnhub.io/api/news?id=ef4ddda3f0dbf2ab2312eed9c2e9350218a2f35ab69a2e7b7f5d813f53ba6026",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756121400,
      "headline": "[Latest] Global Targeted Drug Delivery Market Size/Share Worth USD 39.6 Billion by 2034 at a 15.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 136507917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Targeted Drug Delivery Market size & share revenue was valued at approximately USD 9.8 Billion in 2024 and is expected to reach USD 11.4 Billion in 2025 and is expected to reach around USD 39.6 Billion by 2034, at a CAGR of 15.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Bristol-Myers Squibb, Pfiz",
      "url": "https://finnhub.io/api/news?id=ef4ddda3f0dbf2ab2312eed9c2e9350218a2f35ab69a2e7b7f5d813f53ba6026"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025",
    "summary": "PRINCETON, N.J., August 25, 2025--Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025",
    "url": "https://finnhub.io/api/news?id=78e7cc1dce082eb81148ca42bbf3d1dc55dc868d178a7caf84df48499cf7ba67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756119540,
      "headline": "Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025",
      "id": 136508214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., August 25, 2025--Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025",
      "url": "https://finnhub.io/api/news?id=78e7cc1dce082eb81148ca42bbf3d1dc55dc868d178a7caf84df48499cf7ba67"
    }
  },
  {
    "ts": null,
    "headline": "Should You Revisit Bristol-Myers Squibb Amid Uncertainty Over Pharma Tariffs in 2025?",
    "summary": "If you are eyeing Bristol-Myers Squibb and wondering whether it deserves a spot in your portfolio, you are not alone. At a recent close of $47.92, it is a stock that’s been getting more attention, but for reasons on both sides. Over the past year, its return has been a modest 4.0%, which may not be especially exciting. Looking at a longer period, the three-year and five-year returns come in at -18.5% and -7.0% respectively. Bristol-Myers Squibb has not been delivering strong growth recently,...",
    "url": "https://finnhub.io/api/news?id=434b333fe9021befa36de01cee640c42a72965a990a248cf265ec6356ef5d054",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756117463,
      "headline": "Should You Revisit Bristol-Myers Squibb Amid Uncertainty Over Pharma Tariffs in 2025?",
      "id": 136508215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "If you are eyeing Bristol-Myers Squibb and wondering whether it deserves a spot in your portfolio, you are not alone. At a recent close of $47.92, it is a stock that’s been getting more attention, but for reasons on both sides. Over the past year, its return has been a modest 4.0%, which may not be especially exciting. Looking at a longer period, the three-year and five-year returns come in at -18.5% and -7.0% respectively. Bristol-Myers Squibb has not been delivering strong growth recently,...",
      "url": "https://finnhub.io/api/news?id=434b333fe9021befa36de01cee640c42a72965a990a248cf265ec6356ef5d054"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: presentations scheduled at ESC Congress",
    "summary": "Bristol Myers Squibb says that new clinical and real-world data from its cardiovascular portfolio will be presented at the European Society of Cardiology Congress, which will be held August...",
    "url": "https://finnhub.io/api/news?id=fa2fe1b9da94d7b7d8dc199c59c9f8a73d6c3ea482b873ede2c234412fb3c1d6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756109382,
      "headline": "Bristol Myers: presentations scheduled at ESC Congress",
      "id": 136507376,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb says that new clinical and real-world data from its cardiovascular portfolio will be presented at the European Society of Cardiology Congress, which will be held August...",
      "url": "https://finnhub.io/api/news?id=fa2fe1b9da94d7b7d8dc199c59c9f8a73d6c3ea482b873ede2c234412fb3c1d6"
    }
  }
]